- Mechanism
- Activates GLP-1 and glucagon receptors
- Typical research dose
- 3-9 mg once weekly (clinical trials)
- Route
- Subcutaneous
- Half-life
- Supports once-weekly dosing
- Legal status
- Investigational
Overview
Mazdutide (also known as LY3305677) is a highly anticipated dual-agonist peptide engineered to target both GLP-1 and glucagon receptors. By combining the appetite-suppressing effects of GLP-1 with the fat-burning and energy-expenditure properties of glucagon, it offers a synergistic approach to metabolic regulation. This investigational compound matters because it demonstrates the potential to surpass the weight-loss ceilings of traditional single-receptor therapies, offering new hope for comprehensive obesity and metabolic disease management Gogineni P, Melson E, Papamargaritis D et al., 2024.
Potential Benefits
- Profound Weight Loss: Dual agonism of GLP-1 and glucagon receptors drives superior body weight reduction compared to standard GLP-1 monotherapy Sidrak WR, Kalra S, Kalhan A, 2024.
- Enhanced Fat Burning: Glucagon receptor activation directly stimulates lipolysis and increases resting energy expenditure for targeted fat loss Neff GW, 2025.
- Appetite Suppression: GLP-1 receptor engagement delays gastric emptying and signals satiety to the brain, significantly reducing daily caloric intake Abdelrahman RM, Musa TH, Arbab IA et al., 2025.
- Liver Fat Reduction: The Mazdutide peptide shows strong potential in treating metabolic dysfunction-associated steatotic liver disease (MASLD) by clearing hepatic lipids Neff GW, 2025.
- Improved Glycemic Control: The combination effectively manages blood glucose levels, making it a powerful emerging pharmacotherapy for type 2 diabetes Son JW, le Roux CW, Blüher M et al., 2026.
Side Effects
Common side effects:
- Nausea and vomiting, particularly during dose escalation
- Diarrhea or constipation
- Decreased appetite leading to potential fatigue
- Mild injection site reactions
- Transient increased heart rate
Rare or serious side effects:
- Pancreatitis
- Gallbladder disease (cholelithiasis)
- Severe gastrointestinal distress
- Potential risk of thyroid C-cell tumors (based on rodent GLP-1 data)
Mazdutide is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Dual receptor activation forms the core mechanism of the Mazdutide peptide, engaging both glucagon-like peptide-1 (GLP-1) and glucagon receptors simultaneously. The GLP-1 component enhances glucose-dependent insulin secretion, slows gastric emptying, and promotes satiety in the central nervous system Bailey CJ, Flatt PR, Conlon JM, 2025. This synergistic action effectively curbs caloric intake while maintaining stable blood sugar levels.
Enhanced energy expenditure is driven by the glucagon receptor agonism, a pathway historically viewed with caution but now successfully repurposed to treat obesity Elmendorf AJ, Yousefian M, Kim IM et al., 2026. Glucagon signaling promotes hepatic lipid oxidation, increases thermogenesis, and directly stimulates lipolysis in adipose tissue. By combining these pathways, Mazdutide benefits include not just reduced energy intake, but actively increased fat burning Anderson SL, 2025.
Origin & History
Synthetic development of Mazdutide (originally designated LY3305677 by Eli Lilly and advanced by Innovent Biologics) emerged from the need to surpass the weight-loss plateaus observed with first-generation GLP-1 receptor agonists. Researchers engineered this unimolecular co-agonist to balance the anorectic effects of GLP-1 with the thermogenic properties of glucagon, optimizing the ratio to prevent hyperglycemia Kokkorakis M, Chakhtoura M, Rhayem C et al., 2025. This precise molecular engineering represents a major milestone in hormone-based anti-obesity medications.
Clinical trial progression is currently underway, with the peptide advancing through late-stage human studies to evaluate long-term efficacy and safety. While not yet FDA-approved for general use, its regulatory status remains strictly investigational Abulehia A, Ayesh H, Ayesh O et al., 2026. Ongoing research aims to solidify the Mazdutide side effects profile and establish standardized subcutaneous dosing protocols for future clinical application.